Today’s Rating: Is Imprimis Pharmaceuticals (NASDAQ:IMMY) a Sell? Get to Know What Rodman & Renshaw Thinks

November 28, 2016 - By Clifton Ray

Today's Rating: Is Imprimis Pharmaceuticals (NASDAQ:IMMY) a Sell? Get to Know What Rodman & Renshaw Thinks

Why Rodman & Renshaw Gives Imprimis Pharmaceuticals (NASDAQ:IMMY) $5.00 Price Target

In a analysts note issued to clients and investors on Monday, 28 November, investment analysts at Rodman & Renshaw initiated coverage on shares of Imprimis Pharmaceuticals (NASDAQ:IMMY). The firm set a “Buy” rating with $5.00, giving 81.16% to target.

About 40,480 shares traded hands. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) has declined 34.42% since April 25, 2016 and is downtrending. It has underperformed by 40.44% the S&P500.

Analysts await Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) to report earnings on March, 22.

Insitutional Activity: The institutional sentiment increased to 5.5 in 2016 Q2. Its up 4.30, from 1.2 in 2016Q1. The ratio increased, as 3 funds sold all Imprimis Pharmaceuticals Inc shares owned while 2 reduced positions. 1 funds bought stakes while 5 increased positions. They now own 1.66 million shares or 37.14% less from 2.64 million shares in 2016Q1.

The Illinois-based Bard Assoc Inc has invested 0.13% in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY). Geode Capital Mngmt Limited Liability Company holds 0% or 17,570 shares in its portfolio. Marathon Cap Management holds 0.05% or 25,000 shares in its portfolio. Marathon Asset Management L P has 833,333 shares for 0.17% of their US portfolio. Tower Capital Ltd (Trc) reported 548 shares or 0% of all its holdings. Northern Trust Corporation, a Illinois-based fund reported 43,667 shares. Blackrock Fund has 0% invested in the company for 32,979 shares. Opaleye Mgmt has invested 0.98% of its portfolio in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY). Pnc Financial Services Grp Inc Incorporated holds 0% of its portfolio in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 2,000 shares. Moreover, Manufacturers Life Ins The has 0% invested in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 169 shares. Fincl Bank Of America De, a North Carolina-based fund reported 17,797 shares. Granite Inv Lc accumulated 155,190 shares or 0.05% of the stock. Creative Planning holds 0% or 750 shares in its portfolio. Berson Corrado Invest Llc has 0.08% invested in the company for 31,107 shares. Vanguard Gru Inc Inc owns 168,584 shares or 0% of their US portfolio.

Imprimis Pharmaceuticals, Inc. is engaged in the development, production and dispensing of compounded pharmaceuticals. The company has a market cap of $37.29 million. The Firm operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. It currently has negative earnings. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases.

According to Zacks Investment Research, “Imprimis Pharmaceuticals, Inc. is a pharmaceutical company focused on its proprietary ophthalmology and urology drug formulations. Imprimis recently launched its urology business, which includes a patented formulation to address patients suffering from interstitial cystitis.”

IMMY Company Profile

Imprimis Pharmaceuticals, Inc. (Imprimis), incorporated on January 11, 2006, is engaged in the development, production and dispensing of compounded pharmaceuticals. The Firm operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Firm is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Firm also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas, including oncology, autoimmunity, chronic infectious diseases and endocrine and metabolic diseases.

More recent Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) news were published by: Prnewswire.com which released: “Imprimis Pharmaceuticals Strengthens Senior Leadership Team with Key Hires in …” on August 15, 2016. Also Prnewswire.com published the news titled: “Imprimis Pharmaceuticals Announces Availability of Lower-Cost Option for the …” on October 17, 2016. Prnewswire.com‘s news article titled: “Imprimis Pharmaceuticals Launches Imprimis Cares Access Network (ICAN) to …” with publication date: September 06, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>